Literature DB >> 17101261

Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose.

Florian M E Wagenlehner1, Martina Kinzig-Schippers, Fritz Sörgel, W Weidner, Kurt G Naber.   

Abstract

In a randomised crossover study, 14 volunteers received a single oral dose of 500 mg levofloxacin or 500 mg ciprofloxacin in order to assess plasma concentrations by high-pressure liquid chromatography (up to 24 h), urinary excretion and urinary bactericidal titres (UBTs) at intervals up to 120 h. The median maximum concentration of levofloxacin in plasma was 6.1 mg/L and that of ciprofloxacin was 2.3 mg/L. The median cumulative level of renal excretion of the administered dose of the parent drug was 81.2% for levofloxacin and 36.2% for ciprofloxacin. UBTs were determined for a reference strain and nine clinical uropathogens. The median UBTs of both quinolones measured within the first 12h were between 0 and 1:> or =1024, correlating with the minimum inhibitory concentrations (MICs) of the strains. For Gram-negative strains, the UBTs of both quinolones were comparable despite the lower MICs of ciprofloxacin. During further time courses, however, the UBTs of levofloxacin were significantly higher than those of ciprofloxacin. For Gram-positive strains, for which the MICs of levofloxacin were equal to or lower than those of ciprofloxacin, the UBTs of levofloxacin were already significantly higher from the beginning. It can be concluded that overall the doses of the two tested fluoroquinolones may be considered equivalent with regard to treatment of complicated urinary tract infections, although the recommended dosing is twice daily for ciprofloxacin and once daily for levofloxacin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101261     DOI: 10.1016/j.ijantimicag.2006.07.026

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  17 in total

1.  Duration of antibiotic treatment for urinary tract infection.

Authors:  Jack D Sobel
Journal:  Curr Infect Dis Rep       Date:  2008-11       Impact factor: 3.725

2.  Urinary Tract Infections: Resistance Is Futile.

Authors:  Eric Wenzler; Larry H Danziger
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

3.  Plasmidic qnr Genes Confer Clinical Resistance to Ciprofloxacin under Urinary Tract Physiological Conditions.

Authors:  Guillermo Martín-Gutiérrez; José Manuel Rodríguez-Martínez; Álvaro Pascual; Jerónimo Rodríguez-Beltrán; Jesús Blázquez
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 4.  Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Tam T Van; Emi Minejima; Chiao An Chiu; Susan M Butler-Wu
Journal:  J Clin Microbiol       Date:  2019-06-25       Impact factor: 5.948

5.  Fast photocatalytic degradation of pharmaceutical micropollutants and ecotoxicological effects.

Authors:  Isabella Natali Sora; Davide Fumagalli
Journal:  Environ Sci Pollut Res Int       Date:  2016-09-17       Impact factor: 4.223

6.  Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers.

Authors:  Florian M E Wagenlehner; Fabian Münch; Adrian Pilatz; Birte Bärmann; Wolfgang Weidner; Christine M Wagenlehner; Marion Straubinger; Holger Blenk; Wolfgang Pfister; Michael Kresken; Kurt G Naber
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

7.  Ureolytic Biomineralization Reduces Proteus mirabilis Biofilm Susceptibility to Ciprofloxacin.

Authors:  Xiaobao Li; Nanxi Lu; Hannah R Brady; Aaron I Packman
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

8.  Urinary Tract Physiological Conditions Promote Ciprofloxacin Resistance in Low-Level-Quinolone-Resistant Escherichia coli.

Authors:  Guillermo Martín-Gutiérrez; Jerónimo Rodríguez-Beltrán; José Manuel Rodríguez-Martínez; Coloma Costas; Javier Aznar; Álvaro Pascual; Jesús Blázquez
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

9.  Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus.

Authors:  Theodouli Stergiopoulou; Joseph Meletiadis; Tin Sein; Paraskevi Papaioannidou; Ioannis Tsiouris; Emmanuel Roilides; Thomas J Walsh
Journal:  J Antimicrob Chemother       Date:  2008-12-24       Impact factor: 5.790

10.  Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients.

Authors:  Zhi-Chao Zhang; Feng-Shuo Jin; Dong-Ming Liu; Zhou-Jun Shen; Ying-Hao Sun; Ying-Lu Guo
Journal:  Asian J Androl       Date:  2012-08-06       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.